Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Collaborator: Baxter Healthcare Corporation
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Both prevalent patients or patients newly started on continuous peritoneal dialysis, with or without diabetes mellitus will be considered eligible for study entry.

• For patients newly started on chronic peritoneal dialysis, they will be suitable for recruitment into the study after one month on peritoneal dialysis.

• Patients who provide informed consent for the study

Exclusion Criteria:

• Patients with underlying active malignancy

• Patients with chronic liver disease or liver cirrhosis

• Patients with active infections

• Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis

• Patients who refuse study participation

• Patients with underlying congenital heart disease or rheumatic heart disease

• Patients with poor general condition

• Patients with plans for living related kidney transplant within 2 years

• Female patients with pregnancy

• Patients with history of recurrent hypoglycemia

• Patients with Class III and IV congestive heart failure

• Patients already receiving glitazones treatment at the screening visit